The START Centre for Cancer Research, its preclinical division XenoSTART and Minerva Imaging have announced an expansion of their decade-long partnership to establish the industry’s most comprehensive integrated platform for radiopharmaceutical drug development. This collaboration unites XenoSTART’s repository of clinically annotated Patient-Derived Xenograft (PDX) models with Minerva Imaging’s advanced molecular imaging and radionuclide therapy expertise, creating a single-source solution spanning discovery, translational research, and manufacturing.

“By combining XenoSTART’s deep expertise in clinically annotated PDX models with Minerva Imaging’s state-of-the-art facilities for radiopharmaceutical drug development, we are delivering the gold standard in translational oncology research to target cancers such as prostate. For sponsors, this means faster, smarter, and more predictable development of life-changing therapies that ultimately bring positive impact to patients who need them the most,” said Nick Slack, MBE, Chairman and CEO, START.

Minerva Imaging operates as a fully integrated CRO and CDMO specialised in radiopharmaceuticals. Leveraging more than two decades of expertise in oncology and molecular imaging, Minerva Imaging provides comprehensive imaging modalities (PET/CT, SPECT/CT, MRI), advanced orthotopic in-vivo models, and GMP-certified manufacturing infrastructure for radiopharmaceuticals. This integration enables precise validation of therapeutic mechanisms and supports seamless progression of candidates from preclinical evaluation through clinical translation.

Carsten H Nielsen, PhD, Co-founder and CEO, Minerva Imaging, said, “Our mission is to accelerate the development of novel radiopharmaceuticals through advanced imaging, radionuclide therapy expertise, and GMP manufacturing. By strengthening our collaboration with XenoSTART and START, we are creating a powerful translational bridge for collaborators to move promising therapies from bench to bedside with unprecedented speed and confidence.”

XenoSTART’s PDX models are differentiated by being derived exclusively from tissue obtained from patients treated across START’s global network. These models ensure representation of the most clinically relevant disease states and capture resistance patterns and treatment histories that closely mirror real-world patient populations.

Michael Wick, PhD, Chief Scientific Officer, XenoSTART, added, “XenoSTART provides the most predictive preclinical platform in the industry. Expanding our work with Minerva Imaging ensures that sponsors benefit from seamless integration of these models with advanced radiopharmaceutical development, particularly in prostate cancer where the clinical need is acute.”

Together, START, XenoSTART, and Minerva Imaging are setting a new standard for radiopharmaceutical drug development—accelerating discovery, reducing risk, and delivering therapies that matter the most to patients.